Hi Tech Biosynth Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-12-2024
- Paid Up Capital ₹ 1.00 M
as on 08-12-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 30.01%
(FY 2022)
- Ebitda 30.01%
(FY 2022)
- Net Worth -17.57%
(FY 2022)
- Total Assets -0.05%
(FY 2022)
About Hi Tech Biosynth
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Shilpa Wagh, Raghavendra Gaikaiwari, and Balasubramanian Gopal serve as directors at the Company.
- CIN/LLPIN
U24119PN2016PTC158392
- Company No.
158392
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hi Tech Biosynth?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balasubramanian Gopal  | Director | 12-Feb-2016 | Current |
| Shilpa Wagh | Director | 05-Oct-2016 | Current |
| Raghavendra Gaikaiwari | Director | 12-Feb-2016 | Current |
Financial Performance of Hi Tech Biosynth.
Hi Tech Biosynth Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 30.01% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hi Tech Biosynth?
In 2022, Hi Tech Biosynth had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hi Tech Biosciences India Private LimitedActive 17 years 8 monthsShilpa Wagh and Raghavendra Gaikaiwari are mutual person
Hi-Tech Bio LaboratoriesActive 23 years 5 monthsShilpa Wagh and Raghavendra Gaikaiwari are mutual person
- Sci - Molecules India Private LimitedActive 23 years 9 months
Shilpa Wagh and Raghavendra Gaikaiwari are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hi Tech Biosynth?
Unlock and access historical data on people associated with Hi Tech Biosynth, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hi Tech Biosynth, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hi Tech Biosynth's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
